Redeye comments on Calmarks Q3 2022 report and recent newsflow. Sales in Q3 came in lower than expected, and we lower our FY 2022e and 2023e estimates in terms of sales and EBIT. Our amendments lead to a new fair value range.
ANNONS
Redeye comments on Calmarks Q3 2022 report and recent newsflow. Sales in Q3 came in lower than expected, and we lower our FY 2022e and 2023e estimates in terms of sales and EBIT. Our amendments lead to a new fair value range.